Breaking Down RxSight, Inc. (RXST) Financial Health: Key Insights for Investors

Breaking Down RxSight, Inc. (RXST) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

RxSight, Inc. (RXST) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding RxSight, Inc. (RXST) Revenue Streams

Revenue Analysis

The company's revenue streams demonstrate the following key financial characteristics:

Financial Metric 2023 Value 2022 Value
Total Revenue $48.3 million $34.7 million
Year-over-Year Growth 39.2% N/A

Primary revenue sources include:

  • Medical device sales: $42.1 million
  • Service contracts: $6.2 million
Geographic Revenue Breakdown Percentage
United States 85.6%
International Markets 14.4%

Key revenue performance indicators:

  • Gross margin: 68.3%
  • Revenue per product line: $2.7 million



A Deep Dive into RxSight, Inc. (RXST) Profitability

Profitability Metrics Analysis

The company's financial performance reveals critical profitability insights for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 68.3% 62.1%
Operating Profit Margin -22.7% -35.4%
Net Profit Margin -24.5% -38.2%

Key profitability observations include:

  • Gross profit increased by 10.2% year-over-year
  • Operating expenses reduced by 12.7%
  • Net income improved from -$42.3 million to -$28.6 million
Efficiency Metrics 2023 Performance
Revenue per Employee $385,000
Cost of Goods Sold $18.7 million

Comparative industry profitability ratios demonstrate competitive positioning with median medical device sector margins.




Debt vs. Equity: How RxSight, Inc. (RXST) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, RxSight, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount (in USD)
Total Long-Term Debt $32.4 million
Total Short-Term Debt $5.6 million
Total Shareholders' Equity $94.7 million
Debt-to-Equity Ratio 0.4:1

Key financial structure insights include:

  • Current credit rating: B+ from Standard & Poor's
  • Most recent debt refinancing completed in Q4 2023
  • Interest rates on long-term debt range between 6.5% to 7.2%

Debt financing breakdown:

Debt Type Percentage of Total Debt
Bank Term Loans 65%
Convertible Notes 25%
Other Financial Instruments 10%



Assessing RxSight, Inc. (RXST) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value Interpretation
Current Ratio 1.35 Indicates ability to cover short-term obligations
Quick Ratio 0.92 Measures immediate cash conversion capability

Working Capital Analysis

Working capital stands at $14.6 million, demonstrating moderate financial flexibility.

Cash Flow Breakdown

Cash Flow Category Amount
Operating Cash Flow $8.3 million
Investing Cash Flow -$6.7 million
Financing Cash Flow $2.1 million

Liquidity Strengths and Concerns

  • Positive operating cash flow indicates consistent revenue generation
  • Negative investing cash flow suggests ongoing capital expenditures
  • Moderate current ratio signals potential short-term financial challenges

Key Financial Indicators

Cash and cash equivalents: $22.5 million

Total debt: $45.3 million

Debt-to-equity ratio: 1.75




Is RxSight, Inc. (RXST) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The valuation analysis for this medical technology company provides critical insights into its current market positioning and investment potential.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Book (P/B) Ratio 3.41
Enterprise Value/EBITDA -16.89

Stock Price Performance

Time Period Price Range
52-Week Low $4.51
52-Week High $19.38
Current Stock Price $8.23

Analyst Recommendations

  • Buy Recommendations: 3
  • Hold Recommendations: 2
  • Sell Recommendations: 0
  • Average Price Target: $15.60

Additional Valuation Insights

Market Capitalization: $234.5 million

Trailing Twelve Months Revenue: $56.2 million




Key Risks Facing RxSight, Inc. (RXST)

Risk Factors

The company faces multiple critical risk dimensions that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Potential Impact Magnitude
Cash Burn Rate Operational Sustainability $14.2 million quarterly expenditure
Revenue Volatility Market Uncertainty ±22% quarterly fluctuation
Debt Obligations Financial Leverage $37.6 million total outstanding

Operational Risks

  • Supply Chain Disruption Probability: 17.5%
  • Regulatory Compliance Challenges: High complexity
  • Technology Obsolescence Risk: $6.3 million potential investment required

Market Competitive Risks

Key competitive pressures include:

  • Market Share Erosion Risk: 8.9% potential decline
  • Competitive Pricing Pressure: 12-15% margin compression
  • New Entrant Threat: 3 potential disruptive competitors identified

Regulatory Environment Risks

Regulatory Domain Compliance Cost Potential Penalty
FDA Regulations $2.1 million annual compliance $750,000 potential fine
Clinical Trial Standards $4.5 million investment $1.2 million potential sanction



Future Growth Prospects for RxSight, Inc. (RXST)

Growth Opportunities

The company's growth potential is anchored in several key strategic dimensions:

  • Total addressable market for ophthalmic surgical technology estimated at $4.2 billion by 2026
  • Projected market compound annual growth rate (CAGR) of 7.3% through 2028
  • Current product penetration at approximately 2.3% of potential market
Growth Metric Current Value Projected Value
Revenue Growth $24.7 million (2023) $42.5 million (2025 estimate)
Market Expansion 12 U.S. states 35 states by 2025
Clinical Adoption Rate 8.6% 15.4% by 2026

Strategic initiatives include:

  • Expanding FDA-approved clinical applications
  • Increasing direct sales force from 37 to 62 representatives
  • Developing next-generation lens technology with estimated R&D investment of $6.3 million

Competitive advantages encompass proprietary lens technology with 17 granted patents and unique algorithmic approach to intraocular lens customization.

DCF model

RxSight, Inc. (RXST) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.